Q4 Earnings Estimate for Balchem Issued By HC Wainwright

Balchem Co. (NASDAQ:BCPC) – Equities researchers at HC Wainwright issued their Q4 2026 earnings estimates for shares of Balchem in a research note issued to investors on Monday, February 24th. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will post earnings per share of $1.22 for the quarter. HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share.

Balchem (NASDAQ:BCPC) last announced its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The firm had revenue of $240.00 million during the quarter, compared to analyst estimates of $239.96 million.

Separately, StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research note on Monday, October 28th.

Balchem Stock Performance

Shares of BCPC opened at $165.57 on Tuesday. Balchem has a 12 month low of $137.69 and a 12 month high of $186.03. The stock has a fifty day moving average price of $161.98 and a 200-day moving average price of $169.37. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.38 billion, a PE ratio of 42.13, a P/E/G ratio of 4.41 and a beta of 0.69.

Balchem Increases Dividend

The business also recently declared an annual dividend, which was paid on Friday, January 17th. Shareholders of record on Thursday, December 26th were issued a $0.87 dividend. The ex-dividend date was Thursday, December 26th. This represents a dividend yield of 0.4%. This is a boost from Balchem’s previous annual dividend of $0.79. Balchem’s dividend payout ratio (DPR) is currently 22.14%.

Institutional Investors Weigh In On Balchem

Large investors have recently made changes to their positions in the stock. Watts Gwilliam & Co. LLC lifted its position in Balchem by 63.7% during the 4th quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company’s stock worth $5,438,000 after acquiring an additional 13,642 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Balchem by 1.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company’s stock valued at $80,782,000 after buying an additional 7,721 shares during the period. Stifel Financial Corp boosted its stake in shares of Balchem by 26.2% in the third quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company’s stock worth $2,093,000 after buying an additional 2,467 shares during the last quarter. Apollon Wealth Management LLC acquired a new stake in Balchem during the fourth quarter worth about $503,000. Finally, Congress Asset Management Co. lifted its holdings in Balchem by 5.4% in the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company’s stock valued at $51,769,000 after acquiring an additional 16,170 shares during the period. 87.91% of the stock is owned by hedge funds and other institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.